Annual and transition report of foreign private issuers pursuant to Section 13 or 15(d)

Supplementary Financial Statement Information (Details) - Schedule of changes in deferred revenues relating to goods

v3.21.1
Supplementary Financial Statement Information (Details) - Schedule of changes in deferred revenues relating to goods - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Schedule of changes in deferred revenues relating to goods [Abstract]      
Balance at beginning of year $ (942) [1] $ (1,950) [1]
Contract liability recognized during the period (270) (1,959)
Revenue recognized during the period 1,005 1,008 9
Balance at end of year [1] (207) (942) (1,950)
Contract liability presented in current liabilities (207) (942) (970)
Contract liability presented in non-current liabilities $ (980)
[1] Balance for the years ended December 31, 2018 and 2019 represents the unfulfilled performance obligation related to First BioInk.